Effect of Atorvastatin as a Renal Protection in Patients With Systemic

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT00497666` - Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study	N/A

See also

Status

Clinical Trial

Phase

Not yet recruiting

NCT00497666 - Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05946122
Study type	Interventional
Source	Minia University
Contact
Status	Recruiting
Phase	Phase 1
Start date	May 30, 2023
Completion date	December 30, 2023

Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms